Patents Assigned to CENTOGENE AG
-
Patent number: 10690682Abstract: The present invention is related to a method for diagnosing metachromatic leukodystrophy in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the sample is selected from the group consisting of blood, dried blood, serum and plasma and wherein the biomarker is different from an enzyme.Type: GrantFiled: December 11, 2013Date of Patent: June 23, 2020Assignee: Centogene AGInventors: Arndt Rolfs, Hermann Mascher
-
Patent number: 10422789Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject.Type: GrantFiled: September 11, 2017Date of Patent: September 24, 2019Assignee: Centogene AGInventors: Arndt Rolfs, Hermann Mascher
-
Patent number: 10420754Abstract: The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: GrantFiled: June 11, 2018Date of Patent: September 24, 2019Assignee: Centogene AGInventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Anahit Pews-Davtyan
-
Publication number: 20190201554Abstract: The present invention is related to the in vitro use of lyso-Gb1 as a draggable target in the development of a drug, and to antagonist of lyso-Gb1 for use in the treatment and/or prevention of a disease, wherein the disease is Gaucher disease or Parkinson's disease.Type: ApplicationFiled: July 3, 2017Publication date: July 4, 2019Applicant: Centogene AGInventors: Claudia COZMA, Peter BAUER
-
Patent number: 10302664Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the biomarker is compound 509.Type: GrantFiled: May 14, 2014Date of Patent: May 28, 2019Assignee: Centogene AGInventors: Arndt Rolfs, Hermann Mascher
-
Publication number: 20180203024Abstract: The present invention is related to a method for diagnosing Farber's disease in a subject, wherein the method comprises detecting C26 ceramide in a sample from the subject.Type: ApplicationFiled: July 8, 2016Publication date: July 19, 2018Applicant: CENTOGENE AGInventors: Arndt Rolts, Claudia Cozma
-
Patent number: 9993463Abstract: The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: GrantFiled: December 10, 2013Date of Patent: June 12, 2018Assignee: Centogene AGInventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Arndt Rolfs, Anahit Pews-Davtyan
-
Patent number: 9910033Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject.Type: GrantFiled: November 15, 2012Date of Patent: March 6, 2018Assignee: Centogene AGInventors: Arndt Rolfs, Hermann Mascher
-
Patent number: 9724331Abstract: The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of leukemia, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: GrantFiled: December 10, 2013Date of Patent: August 8, 2017Assignee: Centogene AGInventors: Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Arndt Rolfs, Anahit Pews-Davtyan, Christian Eisenloeffel
-
Publication number: 20160109470Abstract: The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the biomarker is compound 509.Type: ApplicationFiled: May 14, 2014Publication date: April 21, 2016Applicants: Pharm-analyt Labor GmbH, Centogene AGInventors: ARNDT ROLFS, HERMANN MASCHER
-
Publication number: 20150313882Abstract: The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: ApplicationFiled: December 10, 2013Publication date: November 5, 2015Applicant: CENTOGENE AGInventors: MATTHIAS BELLER, JAN LUKAS, MORITZ FRECH, CHRISTIAN JUNGHANSS, ARNDT ROLFS, ANAHIT PEWS-DAVTYAN
-
Publication number: 20150316563Abstract: The present invention is related to a method for diagnosing metachromatic leukodystrophy in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the sample is selected from the group consisting of blood, dried blood, serum and plasma and wherein the biomarker is different from an enzyme.Type: ApplicationFiled: December 11, 2013Publication date: November 5, 2015Applicants: PHARM-ANALYT LABOR GMBH, CENTOGENE AGInventors: ARNDT ROLFS, HERMANN MASCHER
-
Publication number: 20150306070Abstract: The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of leukemia, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.Type: ApplicationFiled: December 10, 2013Publication date: October 29, 2015Applicant: CENTOGENE AGInventors: MATTHIAS BELLER, JAN LUKAS, MORITZ FRECH, CHRISTIAN JUNGHANSS, ARNDT ROLFS, ANAHIT PEWS-DAVTYAN, CHRISTIAN EISENLOEFFEL